Page last updated: 2024-11-06

supidimide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Supidimide is a cyclic imide derivative that has been studied for its potential biological activity. It has shown to exhibit a variety of pharmacological effects, including anti-inflammatory, analgesic, and anticonvulsant properties. The synthesis of supidimide typically involves a multi-step process, starting with the reaction of an appropriate amine with a cyclic anhydride. The compound's importance lies in its potential therapeutic applications, and researchers are exploring its mechanisms of action and its efficacy in various disease models. The study of supidimide is motivated by its promising pharmacological profile and its potential to contribute to the development of new drugs.'

supidimide: non-teratogenic analog of thalidomide; has mild tranquilizing action; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID39528
CHEMBL ID72115
SCHEMBL ID828138
MeSH IDM0090385

Synonyms (25)

Synonym
2-(2-oxo-3-piperidyl)-1,2-benzisothiazolin-3-one 1,1-dioxide
supidimidum [inn-latin]
supidimide
2,3-dihydro-2-(2-oxo-3-piperidyl)-1,2-benzisothiazol-3-on 1,1-dioxid
supidimide [inn]
3-(2,3-dihydro-1,1-dioxido-3-oxo-1,2-benzisothiazol-2-yl)-2-oxopiperidine
cg 3033
1,2-benzisothiazolin-3-one, 2-(2-oxo-3-piperidyl)-, 1,1-dioxide
em 87
supidimida [inn-spanish]
einecs 256-490-3
cg-3033
supimide
CHEMBL72115
49785-74-2
l2gwr3us1g ,
supidimidum
supidimida
unii-l2gwr3us1g
SCHEMBL828138
1,2-benzisothiazol-3(2h)-one, 2-(2-oxo-3-piperidinyl)-, 1,1-dioxide
(+/-)-supidimide; cg 3033; em 87
Q27282622
()-supidimide; cg 3033; em 87
DTXSID40866142

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pretreatment with supidimide at greater than or equal to 150 mg/kg suppresses the early poststress rise in cAMP and the delayed TH induction."( Influence of sedatives on stress-induced trans-synaptic induction of tyrosine hydroxylase.
Flohé, L; Hennies, HH, 1985
)
0.59

Dosage Studied

ExcerptRelevanceReference
" Only after subchronic treatment with an elevated dosage of supidimide (greater than or equal to 150 mg/kg) is a reversible induction of cytochrome P-450 observed."( The metabolic fate of supidimide in the rat.
Becker, R; Flohé, L; Frankus, E; Graudums, I; Günzler, WA; Helm, FC, 1982
)
0.82
" Ten of the studies are dose-response evaluations."( Sleep spindles: pharmacological effects in humans.
Hirshkowitz, M; Karacan, I; Thornby, JI, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID185281Inhibition of microvessel outgrowth in the rat aortic ring assay2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (68.42)18.7374
1990's5 (26.32)18.2507
2000's1 (5.26)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.98 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.03 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.26%)5.53%
Reviews1 (5.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (89.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]